XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT REPORTING (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SCHEDULE OF BREAKDOWN OF SIGNIFICANT OPERATING EXPENSES

                 
   Three months ended June 30,   Six months ended June 30, 
   2025   2024   2025   2024 
Revenue  $-   $47   $-   $94 
Cost of revenues   -    95    -    156 
Gross profit (loss)   -    (48)   -    (62)
                     
Operating expenses:                    
Research and development by significant expense:                    
MSA/license fees   663    812    1,300    1,625 
Study fees   60    88    412    152 
Professional fees   202    (15)   358    88 
Payroll and related   114    61    211    386 
Other1   97    41    164    194 
Research and development   1,136    987    2,445    2,445 
                     
General and administrative by significant expense:                    
Stock-based compensation   353    408    839    644 
Payroll and related2   428    335    821    868 
Professional fees2   440    999    826    2,283 
Occupancy expense   8    1,899    15    3,800 
Other2   136    255    285    616 
General and administrative   1,365    3,896    2,786    8,211 
                     
Total operating expenses   2,501    4,883    5,231    10,656 
                     
Loss from operations   (2,501)   (4,931)   (5,231)   (10,718)
                     
Forward sales contract expense   (512)   -    (5,847)   - 
Change in fair value of warrant liabilities   -    136    1    66 
Change in fair value of contingent consideration   -    66    -    66 
Interest (expense) income, net   -    (797)   5    (1,583)
Other expense, net   (123)   -    (258)   - 
Total other expense, net   (635)   (595)   (6,099)   (1,451)
                     
Loss before income taxes   (3,136)   (5,526)   (11,330)   (12,169)
Provision for income taxes   (3)   (3)   (11)   (7)
                     
Net loss  $(3,139)  $(5,529)  $(11,341)  $(12,176)

 

   June 30, 2025   December 31, 2024 
           
Cash  $4,315   $1,729 

 

1Other includes certain lab supply expenses, amounts related to the close out of a former clinical trial, allocated occupancy costs, stock-based compensation, and depreciation.

 

2Other includes expenses related to insurance, information technology, travel, banking, depreciation and other miscellaneous expenses.